MEDICLIN AG (MED.DE) Stock Fundamental Analysis

FRA:MED • DE0006595101

3.96 EUR
+0.1 (+2.59%)
Last: Feb 27, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

6

We assign a fundamental rating of 6 out of 10 to MED. MED was compared to 32 industry peers in the Health Care Providers & Services industry. MED has an excellent profitability rating, but there are some minor concerns on its financial health. MED may be a bit undervalued, certainly considering the very reasonable score on growth


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • In the past year MED was profitable.
  • In the past year MED had a positive cash flow from operations.
  • The reported net income has been mixed in the past 5 years: MED reported negative net income in multiple years.
  • In the past 5 years MED always reported a positive cash flow from operatings.
MED.DE Yearly Net Income VS EBIT VS OCF VS FCFMED.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M 80M 100M

1.2 Ratios

  • The Return On Assets of MED (3.85%) is better than 68.75% of its industry peers.
  • Looking at the Return On Equity, with a value of 14.15%, MED is in the better half of the industry, outperforming 78.13% of the companies in the same industry.
  • MED's Return On Invested Capital of 7.06% is fine compared to the rest of the industry. MED outperforms 71.88% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for MED is below the industry average of 6.99%.
  • The last Return On Invested Capital (7.06%) for MED is above the 3 year average (3.46%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 3.85%
ROE 14.15%
ROIC 7.06%
ROA(3y)0.85%
ROA(5y)0.34%
ROE(3y)3.39%
ROE(5y)1.18%
ROIC(3y)3.46%
ROIC(5y)2.35%
MED.DE Yearly ROA, ROE, ROICMED.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5 -5 10

1.3 Margins

  • MED has a Profit Margin of 4.40%. This is in the better half of the industry: MED outperforms 71.88% of its industry peers.
  • MED's Profit Margin has improved in the last couple of years.
  • MED has a better Operating Margin (8.52%) than 71.88% of its industry peers.
  • MED's Operating Margin has improved in the last couple of years.
  • MED has a Gross Margin of 84.08%. This is amongst the best in the industry. MED outperforms 81.25% of its industry peers.
  • In the last couple of years the Gross Margin of MED has remained more or less at the same level.
Industry RankSector Rank
OM 8.52%
PM (TTM) 4.4%
GM 84.08%
OM growth 3Y67.11%
OM growth 5Y19.19%
PM growth 3Y148.06%
PM growth 5Y18.19%
GM growth 3Y0.37%
GM growth 5Y0.18%
MED.DE Yearly Profit, Operating, Gross MarginsMED.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so MED is still creating some value.
  • The number of shares outstanding for MED remains at a similar level compared to 1 year ago.
  • Compared to 5 years ago, MED has about the same amount of shares outstanding.
  • Compared to 1 year ago, MED has an improved debt to assets ratio.
MED.DE Yearly Shares OutstandingMED.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
MED.DE Yearly Total Debt VS Total AssetsMED.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

  • MED has an Altman-Z score of 1.60. This is a bad value and indicates that MED is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of MED (1.60) is comparable to the rest of the industry.
  • MED has a debt to FCF ratio of 9.63. This is a negative value and a sign of low solvency as MED would need 9.63 years to pay back of all of its debts.
  • MED has a Debt to FCF ratio of 9.63. This is comparable to the rest of the industry: MED outperforms 53.13% of its industry peers.
  • A Debt/Equity ratio of 1.69 is on the high side and indicates that MED has dependencies on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 1.69, MED is doing worse than 62.50% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 1.69
Debt/FCF 9.63
Altman-Z 1.6
ROIC/WACC1.44
WACC4.89%
MED.DE Yearly LT Debt VS Equity VS FCFMED.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M 400M

2.3 Liquidity

  • A Current Ratio of 1.93 indicates that MED should not have too much problems paying its short term obligations.
  • The Current ratio of MED (1.93) is better than 87.50% of its industry peers.
  • A Quick Ratio of 1.89 indicates that MED should not have too much problems paying its short term obligations.
  • MED has a better Quick ratio (1.89) than 90.63% of its industry peers.
Industry RankSector Rank
Current Ratio 1.93
Quick Ratio 1.89
MED.DE Yearly Current Assets VS Current LiabilitesMED.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • MED shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 414.18%, which is quite impressive.
  • MED shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 20.79% yearly.
  • The Revenue has been growing slightly by 3.40% in the past year.
  • Measured over the past years, MED shows a small growth in Revenue. The Revenue has been growing by 2.19% on average per year.
EPS 1Y (TTM)414.18%
EPS 3Y157.01%
EPS 5Y20.79%
EPS Q2Q%7.67%
Revenue 1Y (TTM)3.4%
Revenue growth 3Y3.65%
Revenue growth 5Y2.19%
Sales Q2Q%7.96%

3.2 Future

  • MED is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 22.30% yearly.
  • The Revenue is expected to grow by 3.41% on average over the next years.
EPS Next Y78.05%
EPS Next 2Y34.35%
EPS Next 3Y22.3%
EPS Next 5YN/A
Revenue Next Year5.81%
Revenue Next 2Y4.12%
Revenue Next 3Y3.41%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
MED.DE Yearly Revenue VS EstimatesMED.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 200M 400M 600M 800M
MED.DE Yearly EPS VS EstimatesMED.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 0.2 0.4 0.6

More info and screens

Find the best growth stocksShow best growing peers

9

4. Valuation

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 5.35 indicates a rather cheap valuation of MED.
  • 100.00% of the companies in the same industry are more expensive than MED, based on the Price/Earnings ratio.
  • When comparing the Price/Earnings ratio of MED to the average of the S&P500 Index (27.10), we can say MED is valued rather cheaply.
  • The Price/Forward Earnings ratio is 5.30, which indicates a rather cheap valuation of MED.
  • Based on the Price/Forward Earnings ratio, MED is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
  • When comparing the Price/Forward Earnings ratio of MED to the average of the S&P500 Index (28.06), we can say MED is valued rather cheaply.
Industry RankSector Rank
PE 5.35
Fwd PE 5.3
MED.DE Price Earnings VS Forward Price EarningsMED.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • MED's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. MED is cheaper than 96.88% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, MED is valued cheaply inside the industry as 87.50% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 4.05
EV/EBITDA 2.94
MED.DE Per share dataMED.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

  • MED's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The decent profitability rating of MED may justify a higher PE ratio.
  • A more expensive valuation may be justified as MED's earnings are expected to grow with 22.30% in the coming years.
PEG (NY)0.07
PEG (5Y)0.26
EPS Next 2Y34.35%
EPS Next 3Y22.3%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

2

5. Dividend

5.1 Amount

  • With a Yearly Dividend Yield of 1.04%, MED has a reasonable but not impressive dividend return.
  • MED's Dividend Yield is comparable with the industry average which is at 1.65.
  • Compared to an average S&P500 Dividend Yield of 1.80, MED's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 1.04%

5.2 History

Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
MED.DE Yearly Dividends per shareMED.DE Yearly Dividends per shareYearly Dividends per share 2019 2025 0.01 0.02 0.03 0.04

5.3 Sustainability

DPN/A
EPS Next 2Y34.35%
EPS Next 3Y22.3%
MED.DE Yearly Income VS Free CF VS DividendMED.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M 80M

More info and screens

Find the best dividend stocksShow peers with best dividend

MEDICLIN AG

FRA:MED (2/27/2026, 7:00:00 PM)

3.96

+0.1 (+2.59%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-04
Earnings (Next)03-26
Inst Owners0.96%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap188.10M
Revenue(TTM)797.34M
Net Income(TTM)35.05M
Analysts80
Price Target5.87 (48.23%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 1.04%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)22.34%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)16.8%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0.72%
Revenue NY rev (3m)1.2%
Valuation
Industry RankSector Rank
PE 5.35
Fwd PE 5.3
P/S 0.24
P/FCF 4.05
P/OCF 1.95
P/B 0.76
P/tB 0.84
EV/EBITDA 2.94
EPS(TTM)0.74
EY18.69%
EPS(NY)0.75
Fwd EY18.87%
FCF(TTM)0.98
FCFY24.72%
OCF(TTM)2.04
OCFY51.39%
SpS16.79
BVpS5.21
TBVpS4.7
PEG (NY)0.07
PEG (5Y)0.26
Graham Number9.32
Profitability
Industry RankSector Rank
ROA 3.85%
ROE 14.15%
ROCE 9.1%
ROIC 7.06%
ROICexc 9.61%
ROICexgc 10.05%
OM 8.52%
PM (TTM) 4.4%
GM 84.08%
FCFM 5.83%
ROA(3y)0.85%
ROA(5y)0.34%
ROE(3y)3.39%
ROE(5y)1.18%
ROIC(3y)3.46%
ROIC(5y)2.35%
ROICexc(3y)4.47%
ROICexc(5y)3.03%
ROICexgc(3y)4.72%
ROICexgc(5y)3.22%
ROCE(3y)4.46%
ROCE(5y)3.03%
ROICexgc growth 3Y64.29%
ROICexgc growth 5Y26.18%
ROICexc growth 3Y68.25%
ROICexc growth 5Y27.23%
OM growth 3Y67.11%
OM growth 5Y19.19%
PM growth 3Y148.06%
PM growth 5Y18.19%
GM growth 3Y0.37%
GM growth 5Y0.18%
F-Score8
Asset Turnover0.88
Health
Industry RankSector Rank
Debt/Equity 1.69
Debt/FCF 9.63
Debt/EBITDA 3.49
Cap/Depr 96.09%
Cap/Sales 6.29%
Interest Coverage 3.18
Cash Conversion 80.47%
Profit Quality 132.66%
Current Ratio 1.93
Quick Ratio 1.89
Altman-Z 1.6
F-Score8
WACC4.89%
ROIC/WACC1.44
Cap/Depr(3y)56.34%
Cap/Depr(5y)45.08%
Cap/Sales(3y)4.78%
Cap/Sales(5y)4.13%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)414.18%
EPS 3Y157.01%
EPS 5Y20.79%
EPS Q2Q%7.67%
EPS Next Y78.05%
EPS Next 2Y34.35%
EPS Next 3Y22.3%
EPS Next 5YN/A
Revenue 1Y (TTM)3.4%
Revenue growth 3Y3.65%
Revenue growth 5Y2.19%
Sales Q2Q%7.96%
Revenue Next Year5.81%
Revenue Next 2Y4.12%
Revenue Next 3Y3.41%
Revenue Next 5YN/A
EBIT growth 1Y281.51%
EBIT growth 3Y73.21%
EBIT growth 5Y21.8%
EBIT Next Year143.72%
EBIT Next 3Y33.62%
EBIT Next 5YN/A
FCF growth 1Y196.83%
FCF growth 3Y-17.96%
FCF growth 5Y7.78%
OCF growth 1Y96.85%
OCF growth 3Y-0.57%
OCF growth 5Y2.97%

MEDICLIN AG / MED.DE FAQ

What is the ChartMill fundamental rating of MEDICLIN AG (MED.DE) stock?

ChartMill assigns a fundamental rating of 6 / 10 to MED.DE.


Can you provide the valuation status for MEDICLIN AG?

ChartMill assigns a valuation rating of 9 / 10 to MEDICLIN AG (MED.DE). This can be considered as Undervalued.


Can you provide the profitability details for MEDICLIN AG?

MEDICLIN AG (MED.DE) has a profitability rating of 7 / 10.


Can you provide the PE and PB ratios for MED stock?

The Price/Earnings (PE) ratio for MEDICLIN AG (MED.DE) is 5.35 and the Price/Book (PB) ratio is 0.76.


What is the financial health of MEDICLIN AG (MED.DE) stock?

The financial health rating of MEDICLIN AG (MED.DE) is 4 / 10.